Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Dr. Reddy’s Laboratories Limited (ADR) (RDY), Abbott Laboratories (ABT): Positive Outlook for the Generic Version of Depakote ER

According to the company’s investor presentation in June, the company experienced a 26% year-over-year growth in revenues exceeding $2 billion in the 2013 fiscal year. The revenues increased significantly in all the regions except Europe. The earnings before interest, taxes, depreciation and amortization (EBITDA) growth was 36% year-over-year. The company’s current and non-current liabilities decreased by 0.3%.

Game plans of the competitors
According to a company press release, Mylan Inc. (NASDAQ:MYL) also launched the generic version of Depakote ER back in 2011. Recently, Mylan Inc. (NASDAQ:MYL) launched generic versions of two new drugs. In mid-July it launched northindrone tablets, which is the generic version of Watson Laboratories’ Nor-Q.D. tablets, and fenofibric acid delayed capsules, which is the first generic version of Abbot Laboratries’ Trilipix capsules. Northindrone tablets had U.S. sales of approximately $39 million for the 12 months ending on March 31, while fenofibric acid delayed capsules had sales of approximately $553.6 million for the same period and market.

Bottom line
After the launch of a new generic drug to meet an increasing demand in the U.S. market, Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY) is expected to register strong returns in upcoming quarters. The company’s financial performance is also getting stronger, assuring higher returns for investors. It also pays one of the highest dividends in the industry, encouraging more investors to invest in its stock.

The article Positive Outlook for the Generic Version of Depakote ER originally appeared on Fool.com and is written by usman iftikhar.

usman iftikhar has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.